An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
A phase 3 trial of Apalutamide and Bicalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.
Overview
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS is a phase 3 interventional study registered as NCT02531516 by Aragon Pharmaceuticals, Inc., with 1503 participants enrolled, started 2015-11-19 and due to reach its primary completion in 2027-03-01. Interventions recorded: Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist) and 74-80 Grays (units of radiation).
Similar pages
not linked directly; found by shared links- TrialA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Apalutamide, Prostate cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Shares Apalutamide and the tag pipeline.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TreatmentJNJ-87189401
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.